Salah Sommakia1, Naredos H Almaw1, Sandra H Lee1, Dinesh K A Ramadurai1, Iosif Taleb1, Christos P Kyriakopoulos1, Chris J Stubben2, Jing Ling1, Robert A Campbell3, Rami A Alharethi4, William T Caine4, Sutip Navankasattusas1, Guillaume L Hoareau5, Anu E Abraham6, James C Fang6,4, Craig H Selzman1,7,4, Stavros G Drakos6,4, Dipayan Chaudhuri6. 1. Nora Eccles Harrison Cardiovascular Research and Training Institute (S.S., N.H.A., S.H.L., D.K.A.R., I.T., C.P.K., J.L., S.N., G.L.H., C.H.S., S.G.D., D.C.), University of Utah, Salt Lake City. 2. Bioinformatics Shared Resource, Huntsman Cancer Institute (C.J.S.), University of Utah, Salt Lake City. 3. Division of General Medicine, Department of Internal Medicine, Program in Molecular Medicine (R.A.C.), University of Utah, Salt Lake City. 4. Utah Transplant Affiliated Hospitals Cardiac Transplant Program, University of Utah Healthcare and School of Medicine, Intermountain Medical Center, Salt Lake Veterans Affairs Health Care System (R.A.A., W.T.C., C.H.S., S.G.D., J.C.F.). 5. Division of Emergency Medicine (G.L.H.), University of Utah, Salt Lake City. 6. Department of Surgery and Division of Cardiovascular Medicine, Department of Internal Medicine (A.E.A., J.C.F., S.G.D., D.C.), University of Utah, Salt Lake City. 7. Division of Cardiothoracic Surgery (C.H.S.), University of Utah, Salt Lake City.
Abstract
BACKGROUND: Extrinsic control of cardiomyocyte metabolism is poorly understood in heart failure (HF). FGF21 (Fibroblast growth factor 21), a hormonal regulator of metabolism produced mainly in the liver and adipose tissue, is a prime candidate for such signaling. METHODS: To investigate this further, we examined blood and tissue obtained from human subjects with end-stage HF with reduced ejection fraction at the time of left ventricular assist device implantation and correlated serum FGF21 levels with cardiac gene expression, immunohistochemistry, and clinical parameters. RESULTS: Circulating FGF21 levels were substantially elevated in HF with reduced ejection fraction, compared with healthy subjects (HF with reduced ejection fraction: 834.4 [95% CI, 628.4-1040.3] pg/mL, n=40; controls: 146.0 [86.3-205.7] pg/mL, n=20, P=1.9×10-5). There was clear FGF21 staining in diseased cardiomyocytes, and circulating FGF21 levels negatively correlated with the expression of cardiac genes involved in ketone metabolism, consistent with cardiac FGF21 signaling. FGF21 gene expression was very low in failing and nonfailing hearts, suggesting extracardiac production of the circulating hormone. Circulating FGF21 levels were correlated with BNP (B-type natriuretic peptide) and total bilirubin, markers of chronic cardiac and hepatic congestion. CONCLUSIONS: Circulating FGF21 levels are elevated in HF with reduced ejection fraction and appear to bind to the heart. The liver is likely the main extracardiac source. This supports a model of hepatic FGF21 communication to diseased cardiomyocytes, defining a potential cardiohepatic signaling circuit in human HF.
BACKGROUND: Extrinsic control of cardiomyocyte metabolism is poorly understood in heart failure (HF). FGF21 (Fibroblast growth factor 21), a hormonal regulator of metabolism produced mainly in the liver and adipose tissue, is a prime candidate for such signaling. METHODS: To investigate this further, we examined blood and tissue obtained from human subjects with end-stage HF with reduced ejection fraction at the time of left ventricular assist device implantation and correlated serum FGF21 levels with cardiac gene expression, immunohistochemistry, and clinical parameters. RESULTS: Circulating FGF21 levels were substantially elevated in HF with reduced ejection fraction, compared with healthy subjects (HF with reduced ejection fraction: 834.4 [95% CI, 628.4-1040.3] pg/mL, n=40; controls: 146.0 [86.3-205.7] pg/mL, n=20, P=1.9×10-5). There was clear FGF21 staining in diseased cardiomyocytes, and circulating FGF21 levels negatively correlated with the expression of cardiac genes involved in ketone metabolism, consistent with cardiac FGF21 signaling. FGF21 gene expression was very low in failing and nonfailing hearts, suggesting extracardiac production of the circulating hormone. Circulating FGF21 levels were correlated with BNP (B-type natriuretic peptide) and total bilirubin, markers of chronic cardiac and hepatic congestion. CONCLUSIONS: Circulating FGF21 levels are elevated in HF with reduced ejection fraction and appear to bind to the heart. The liver is likely the main extracardiac source. This supports a model of hepatic FGF21 communication to diseased cardiomyocytes, defining a potential cardiohepatic signaling circuit in human HF.
Authors: Hiroshi Kurosu; Mihwa Choi; Yasushi Ogawa; Addie S Dickson; Regina Goetz; Anna V Eliseenkova; Moosa Mohammadi; Kevin P Rosenblatt; Steven A Kliewer; Makoto Kuro-o Journal: J Biol Chem Date: 2007-07-10 Impact factor: 5.157
Authors: Theresia Sarabhai; Sabine Kahl; Julia Szendroedi; Daniel F Markgraf; Oana-Patricia Zaharia; Cristina Barosa; Christian Herder; Frithjof Wickrath; Pavel Bobrov; Jong-Hee Hwang; John Griffith Jones; Michael Roden Journal: JCI Insight Date: 2020-05-21
Authors: Klementina Fon Tacer; Angie L Bookout; Xunshan Ding; Hiroshi Kurosu; George B John; Lei Wang; Regina Goetz; Moosa Mohammadi; Makoto Kuro-o; David J Mangelsdorf; Steven A Kliewer Journal: Mol Endocrinol Date: 2010-07-28
Authors: Xinmei Zhang; Dennis C Y Yeung; Michal Karpisek; David Stejskal; Zhi-Guang Zhou; Feng Liu; Rachel L C Wong; Wing-Sun Chow; Annette W K Tso; Karen S L Lam; Aimin Xu Journal: Diabetes Date: 2008-02-05 Impact factor: 9.461
Authors: Christopher Yanucil; Dominik Kentrup; Xueyi Li; Alexander Grabner; Karla Schramm; Eliana C Martinez; Jinliang Li; Isaac Campos; Brian Czaya; Kylie Heitman; David Westbrook; Adam R Wende; Alexis Sloan; Johanna M Roche; Alessia Fornoni; Michael S Kapiloff; Christian Faul Journal: Sci Rep Date: 2022-05-05 Impact factor: 4.996